@article { , title = {Pharmacological advances in mitochondrial therapy}, abstract = {Mitochondria play a vital role in cellular metabolism and are central mediator of intracellular signalling, cell differentiation, morphogenesis and demise. An increasingly higher number of pathologies is linked with mitochondrial dysfunction, which can arise from either genetic defects affecting core mitochondrial components or malfunctioning pathways impairing mitochondrial homeostasis. As such, mitochondria are considered an important target in several pathologies spanning from neoplastic to neurodegenerative diseases as well as metabolic syndromes. In this review we provide an overview of the state-of-the-art in mitochondrial pharmacology, focusing on the novel compounds that have been generated in the bid to correct mitochondrial aberrations. Our work aims to serve the scientific community working on translational medical science by highlighting the most promising pharmacological approaches to target mitochondrial dysfunction in disease. (C) 2021 The Authors. Published by Elsevier B.V.}, doi = {10.1016/j.ebiom.2021.103244}, publicationstatus = {Published}, publisher = {Elsevier}, url = {https://rvc-repository.worktribe.com/output/1553361}, volume = {65}, keyword = {Mitochondrial diseases, Mitochondrial dysfunction in pathology, Mitochondria-targeted and untargeted agents, DISEASE}, year = {2024}, author = {Singh, A and Faccenda, D and Campanella, M} }